Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 9:42 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 2,991 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Investigational drug Clear all

Conditions: Interstitial Cystitis
Interventions: LiRIS 400 mg, LiRIS Placebo; Drug · Other
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 15
States / cities: Glendora, California • Daytona Beach, Florida • Kansas City, Kansas + 12 more

Conditions: Ocular Comfort
Interventions: Lotrafilcon A test contact lens, Lotrafilcon A control contact lens, Ultra-High Resolution Optical Coherence Tomographer (OCT); Device
Lead sponsor: CIBA VISION; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Healthy, Cognitive Function
Interventions: Qualia Mind, Placebo; Dietary Supplement
Lead sponsor: Neurohacker Collective; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: B-cell Acute Lymphoblastic Leukemia (B-ALL)
Interventions: Surovatamig; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years and older
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 12
States / cities: Birmingham, Alabama • Duarte, California • Los Angeles, California + 9 more

Conditions: Clear Cell Renal Carcinoma
Interventions: MK-3475, Bevacizumab; Drug
Lead sponsor: Arkadiusz Z. Dudek, MD; Other
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 9
States / cities: Chicago, Illinois • Iowa City, Iowa • Ann Arbor, Michigan + 5 more

Conditions: Acute Pancreatitis (AP), Gallstone Pancreatitis, Alcoholic Pancreatitis, Trauma Acute Pancreatitis, Hypertriglyceridemia Acute Pancreatitis, Idiopathic (Unknown) Acute Pancreatitis, Medication Induced Acute Pancreatitis, Cancer Acute Pancreatitis, Miscellaneous (i.e. Acute on Chronic Pancreatitis)
Interventions: Pentoxifylline, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 100 Years
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Healthy
Interventions: Placebo, PF-06818883; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Acute Viral Respiratory Infection
Interventions: PurInf I Botanical Formulation, PurInf II Botanical Formulation, PurInf III Botanical Formulation, PurCo Botanical Formulation, PurPhl Botanical Formulation, PurClo Botanical Formulation; Drug
Lead sponsor: All Natural Medicine Clinic, LLC; Other
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: Opioid Use Disorder, Substance Use Disorder
Interventions: Treatment as Usual (TAU) (Arm 1), Peer Recovery Support Services (PRSS) + TAU (experimental- Arm 2); Behavioral
Lead sponsor: Potomac Health Foundations; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 2
States / cities: Baltimore, Maryland • Rockville, Maryland

Conditions: Secondary Hyperparathyroidism
Interventions: Sensipar (Cinacalcet HCl); Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 16
States / cities: Phoenix, Arizona • Los Angeles, California • Denver, Colorado + 13 more

Conditions: CD30-Positive Diffuse Large B-Cell Lymphoma, Anaplastic Large Cell Lymphoma, T Cell and Null Cell Type, Anaplastic Large Cell Lymphoma, ALK-Positive, Peripheral T-cell Lymphoma, Anaplastic Large Cell Lymphoma, ALK-negative, Non-Hodgkin Lymphoma, Hodgkin Lymphoma
Interventions: C7R.CD30.CAR-EBVST cells; Biological
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 12 Years to 75 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2043
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Healthy Adult Immune Response
Interventions: VRC-HIVMAB095-00-AB (10E8VLS), VRC-HIVMAB075-00-AB (VRC07-523LS); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Vaping, Adolescent, Electronic Cigarette Use, Nicotine, Cannabis
Interventions: Vaping Device Labeling; Other
Lead sponsor: University of Southern California; Other
Eligibility: 11 Years to 19 Years
Enrollment: 3,048 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Metastatic Breast Cancer, Tumor, Muscle Neoplasms, Chronic Pain
Interventions: Method(s)1 Attribution, Method(s)2 Attribution,; Drug
Lead sponsor: DR. DIANE CHISESI NFS. MD. PHD.; Other
Eligibility: 44 Years to 59 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Colorado Springs, Colorado

Conditions: Renal Transplant Rejection
Interventions: Sirolimus, Demographic Data, Medical History, and Donor Data, Blood Draws for Control Group, Blood Draws for Experimental Group, Donor Blood Draws, Donor Information, Kidney Biopsy; Drug · Other · Procedure
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2019
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Obesity
Interventions: TAP® Micro Select Device (Touch Activated Phlebotomy); Device
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Medford, Massachusetts

Conditions: Non-Hodgkin Lymphoma
Interventions: AZD0466; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Duarte, California

Conditions: Prostate Cancer
Interventions: Apalutamide, Abiraterone Acetate, Prednisone, GnRH agonist/antagonist; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 11
States / cities: Chicago, Illinois • Evanston, Illinois • Boston, Massachusetts + 8 more

Conditions: Healthy Volunteer
Interventions: Icovamenib, Icovamenib HPMC; Drug
Lead sponsor: Biomea Fusion Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Teenage Pregnancy
Interventions: Girl2Girl; Behavioral
Lead sponsor: Center for Innovative Public Health Research; Other
Eligibility: 14 Years to 18 Years · Female only
Enrollment: 948 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: San Clemente, California

Conditions: Lassa Fever
Interventions: ARN-75039 high, Intravenous ribavirin, ARN-75039 low; Drug
Lead sponsor: Arisan Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Carlsbad, California

Conditions: Advanced Solid Tumors
Interventions: PX-866; Drug
Lead sponsor: Cascadian Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 2
States / cities: Aurora, Colorado • Houston, Texas

Conditions: Hip Fractures, Analgesia, Opioid Use, Pain, Postoperative
Interventions: Cephalomedullary nailing of extracapsular hip fracture, cephalomedullary nail, Regional Anesthetics; Procedure · Device · Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 60 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy
Interventions: Ramipril10 mg Capsules, single dose, Atlace® 10 mg capsules, single dose; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Austin, Texas

Search by objective public record fields.

Safety, Tolerability and Efficacy Study of LiRIS® 400 mg in Women With Interstitial Cystitis

Ocular Comfort and OCT Observation of Post Lens Clearance and Ocular Tissue Compression

Safety and Efficacy Study of Qualia Mind on Cognition in a Healthy Population

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

Phase Ib and Phase II Studies of MK-3475 in Combination + for Renal Cell Carcinoma:

Pentoxifylline Treatment in Acute Pancreatitis (AP)

Safety and Tolerability of PF-06818883 in Healthy Subjects

Botanical Therapy for Acute Viral Respiratory Infections

Peer Recovery Support Services for Individuals in Recovery Residences on MOUD

Bone Biopsy Study For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease

Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas

Phase I Study to Evaluate a Human Monoclonal Antibody (MAb) 10E8VLS Administered Alone or Concurrently With MAb VRC07-523LS Via Subcutaneous Injection in Healthy Adults

Nicotine and Cannabis Vape Labeling Experiment - Spring 2025

Anastrozole Adjuvant Trial - Study of Anastrozole Compared to NOLVADEX (Tamoxifen Citrate) for Adjuvant Treatment of Early Breast Cancer Clinical Studies), Adjunct Cytotoxic Chemotherapy and Malignant Joint Tumor

Randomized Conversion of Calcineurin-Inhibitors in Renal Allograft Recipients

A Study to Determine the Feasibility of Online Recruitment of People Using an Anti-Obesity Medication for Weight Loss

A Phase I/II Study of AZD0466 as Monotherapy or in Combination With Anticancer Agents in Advanced Non-Hodgkin Lymphoma

Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma

Food Effect Study in Healthy Volunteers

Girl2Girl: Harnessing Text Messaging to Reduce Teenage Pregnancy Among LGB Girls

ARN-75039 Lassa Fever Treatment in West Africa

Phase I Trial of Oral PX-866

Postop Pain Control in Hip Fracture Surgery: Fascia Iliaca Compartment Block Versus Fracture Block

A Relative Bioavailability Study of Ramipril 10 mg Capsules Under Fed Conditions